Breaking News
Shares in Novo Nordisk rose 10% on the results of an early-stage weight loss drug trial
A view of the Novo Nordisk logo at the company’s office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, on March 8, 2024.
Tom Little | Reuters
Shares of Novo Nordisk jumped on Friday after the Danish pharmaceutical giant reported positive early-stage results for its once-weekly anti-obesity drug amicretin.
The trial showed an average weight reduction of 22% in obese and overweight patients after 36 weeks.
Shares were last up 9.5% at 11:02am London time.
This is a developing story. Check again for updates.
